SCHEDULE: Medpace Founder Sells Over $149M in Shares

Medpace Holdings, Inc. founder August J. Troendle significantly reduced his stake, selling common stock worth over $149 million in open market transactions.

Summary

• August J. Troendle, founder of Medpace Holdings, Inc., reported a reduction in his beneficial ownership of the company's common stock.
• Between November 12, 2025, and November 28, 2025, Mr. Troendle sold a total of 248,474 shares in open market transactions.
• The sales occurred at weighted-average prices ranging from approximately $590.19 to $623.12 per share, totaling over $149 million.
• Following these transactions, Mr. Troendle's aggregate beneficial ownership decreased to 5,682,934 shares, representing 20.0% of the class.
• Medpace Investors, LLC, for which Mr. Troendle is the sole manager, beneficially owns 4,733,019 shares, representing 16.6% of the class, with shared voting and dispositive power.

Sentiment

Score: 3

Explanation: The significant insider selling by the company's founder and a major reporting person is generally viewed negatively by the market, indicating a potential lack of confidence or a move to diversify personal assets.

Negatives

• Significant insider selling by the founder and a key reporting person, August J. Troendle, which can be interpreted as a potential lack of confidence or a move to diversify personal holdings.
• The sales occurred over multiple days, indicating a systematic reduction of his stake.

Risks

• The market may interpret the substantial insider selling as a negative signal, potentially leading to downward pressure on the stock price.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

This filing is specific to insider ownership changes and does not provide broader industry context or trends.

Related Party Transactions

• The reported sales of common stock by August J. Troendle, a reporting person and founder, constitute related party transactions in the context of insider dealings.

Stakeholder Impact

• Shareholders may interpret the significant insider selling as a negative signal, potentially leading to downward pressure on the stock price.
• No direct impact on employees, customers, suppliers, or creditors is mentioned in the filing.

Key Dates

Recommendation

The filing reports significant insider selling by the company's founder, August J. Troendle, who reduced his stake by 248,474 shares over several days in November 2025. While this is a factual report of past transactions and not necessarily indicative of future company performance, substantial insider selling can be a bearish signal. Investors should monitor future filings and company performance closely, but for now, a 'hold' recommendation is prudent given the potential for negative market sentiment without further operational context.

Keywords

Medpace Holdings, August J. Troendle, insider selling, common stock, Schedule 13D/A, beneficial ownership, stock sale, equity, institutional ownership